Business
Notification of Site Visit
Notification of Site Visit.
About this update from Hikma Pharmaceuticals Plc
[{"type":"text","content":"\n Hikma Pharmaceuticals Plc\n20 November 2006\n\n NOTIFICATION OF SITE VISIT\n\nLondon, 20 November 2006 - Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK), the\nmultinational pharmaceuticals group, is hosting a site visit in Sintra, Portugal\ntoday.\n\nHikma will provide an overview of its core businesses as well as a tour of its\nInjectable manufacturing facilities, which include the new state-of-the-art\ncephalosporin plant.\n\nNo material new information will be disclosed and there will not be any further\nstatement on current trading. Copies of today's presentations will be posted on\nthe company's website, www.hikma.com.\n\n - ENDS -\n\nEnquiries:\nHikma Pharmaceuticals PLC\n\nSusan Ringdal +44 20 7399 2760\nInvestor Relations Director\n\nBrunswick Group\nJon Coles / Justine McIlroy / Alex Tweed +44 20 7404 5959\n\nAbout Hikma\n\nHikma Pharmaceuticals PLC is a multinational pharmaceutical group focused on\ndeveloping, manufacturing and marketing a broad range of both branded and\nnon-branded generic and in-licensed pharmaceutical products. Hikma's operations\nare conducted through three businesses: Generic, Branded and Injectable\nPharmaceuticals. Hikma's operations are based principally in the United States,\nthe Middle East and North Africa ('MENA') region and Europe. In 2005, the Group\nhad revenue of $262 million and profit attributable to shareholders of $44\nmillion. At 31 December 2005, the Group had over 1,800 employees. For news and\nother information, please visit www.hikma.com.\n\n\n\n\n\n\n This information is provided by RNS\n The company news service from the London Stock Exchange\n \n ","length":1803,"tagName":"div"}]